Nonmyeloablative allogeneic bone marrow transplantation for orbital granulocytic sarcoma associated with t(8;21)(q22;q22) in acute myeloid leukemia

G. Y. Hung; T. J. Chiou; Y. L. Hsieh; P. M. Chen; B. Hwang

doi:10.1038/sj.bmt.1703316

Nonmyeloablative allogeneic bone marrow transplantation for orbital granulocytic sarcoma associated with t(8;21)(q22;q22) in acute myeloid leukemia

G. Y. Hung
, T. J. Chiou
, Y. L. Hsieh
, P. M. Chen
, B. Hwang

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

Abstract

We report a nonmyeloablative allogeneic bone marrow transplant (allo-BMT) from an HLA-matched unrelated donor in a case of acute myeloid leukemia (AML), M2 with t(8;21)(q22;q22) and the presence of orbital granulocytic sarcoma (GS), who had residual tumor after conventional chemotherapy. The course of BMT was well tolerated, with no major procedure-related toxicity. The residual orbital GS regressed completely 4 months after BMT. She is currently 19 months post BMT, disease-free. To our knowledge, this is the first reported pediatric patient with AML, GS and t(8;21)(q22;q22) who received a nonmyeloablative allo-BMT.

Original language	English
Pages (from-to)	67-70
Number of pages	4
Journal	Bone Marrow Transplantation
Volume	29
Issue number	1
DOIs	https://doi.org/10.1038/sj.bmt.1703316
Publication status	Published - 2002
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Acute myeloid leukemia
Granulocytic sarcoma
Nonmyeloablative bone marrow transplantation

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/sj.bmt.1703316

Cite this

@article{db8f78520dc24137b243c38fec34730a,

title = "Nonmyeloablative allogeneic bone marrow transplantation for orbital granulocytic sarcoma associated with t(8;21)(q22;q22) in acute myeloid leukemia",

abstract = "We report a nonmyeloablative allogeneic bone marrow transplant (allo-BMT) from an HLA-matched unrelated donor in a case of acute myeloid leukemia (AML), M2 with t(8;21)(q22;q22) and the presence of orbital granulocytic sarcoma (GS), who had residual tumor after conventional chemotherapy. The course of BMT was well tolerated, with no major procedure-related toxicity. The residual orbital GS regressed completely 4 months after BMT. She is currently 19 months post BMT, disease-free. To our knowledge, this is the first reported pediatric patient with AML, GS and t(8;21)(q22;q22) who received a nonmyeloablative allo-BMT.",

keywords = "Acute myeloid leukemia, Granulocytic sarcoma, Nonmyeloablative bone marrow transplantation",

author = "Hung, \{G. Y.\} and Chiou, \{T. J.\} and Hsieh, \{Y. L.\} and Chen, \{P. M.\} and B. Hwang",

year = "2002",

doi = "10.1038/sj.bmt.1703316",

language = "English",

volume = "29",

pages = "67--70",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - Nonmyeloablative allogeneic bone marrow transplantation for orbital granulocytic sarcoma associated with t(8;21)(q22;q22) in acute myeloid leukemia

AU - Hung, G. Y.

AU - Chiou, T. J.

AU - Hsieh, Y. L.

AU - Chen, P. M.

AU - Hwang, B.

PY - 2002

Y1 - 2002

N2 - We report a nonmyeloablative allogeneic bone marrow transplant (allo-BMT) from an HLA-matched unrelated donor in a case of acute myeloid leukemia (AML), M2 with t(8;21)(q22;q22) and the presence of orbital granulocytic sarcoma (GS), who had residual tumor after conventional chemotherapy. The course of BMT was well tolerated, with no major procedure-related toxicity. The residual orbital GS regressed completely 4 months after BMT. She is currently 19 months post BMT, disease-free. To our knowledge, this is the first reported pediatric patient with AML, GS and t(8;21)(q22;q22) who received a nonmyeloablative allo-BMT.

AB - We report a nonmyeloablative allogeneic bone marrow transplant (allo-BMT) from an HLA-matched unrelated donor in a case of acute myeloid leukemia (AML), M2 with t(8;21)(q22;q22) and the presence of orbital granulocytic sarcoma (GS), who had residual tumor after conventional chemotherapy. The course of BMT was well tolerated, with no major procedure-related toxicity. The residual orbital GS regressed completely 4 months after BMT. She is currently 19 months post BMT, disease-free. To our knowledge, this is the first reported pediatric patient with AML, GS and t(8;21)(q22;q22) who received a nonmyeloablative allo-BMT.

KW - Acute myeloid leukemia

KW - Granulocytic sarcoma

KW - Nonmyeloablative bone marrow transplantation

UR - https://www.scopus.com/pages/publications/85047700146

UR - https://www.scopus.com/pages/publications/85047700146#tab=citedBy

U2 - 10.1038/sj.bmt.1703316

DO - 10.1038/sj.bmt.1703316

M3 - Article

C2 - 11840147

AN - SCOPUS:85047700146

SN - 0268-3369

VL - 29

SP - 67

EP - 70

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 1

ER -

Nonmyeloablative allogeneic bone marrow transplantation for orbital granulocytic sarcoma associated with t(8;21)(q22;q22) in acute myeloid leukemia

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this